JPM vs NRO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NRO exhibits significant fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor operational health. While the fund trades at a slight discount to book value (P/B 0.93) and offers a high dividend yield of 12.32%, these are offset by a severe collapse in earnings growth (-87.90% YoY) and negative profit margins. The lack of an Altman Z-Score and poor liquidity ratios (Quick Ratio 0.21) further underscore the risk profile. Overall, the asset appears to be a high-yield trap with deteriorating fundamentals.
Compare Another Pair
Related Comparisons
JPM vs NRO: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Neuberger Berman Income Funds - Neuberger Real Estate Securities Income Fund Inc. (NRO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.